Optimal dose selection in oncology biologics development: Need for a paradigm shift.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.3093
Abstract: 3093 Background: In oncology, the recommended phase 2 dose (RP2D) is typically selected from the first-in-patient (FIP) dose escalation and then carried forward to late stage trials. The RP2D is often informed by limited data… read more here.
Keywords: oncology biologics; optimization; dose selection; oncology ... See more keywords
Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics.
Sign Up to like & getrecommendations! Published in 2019 at "Future oncology"
DOI: 10.2217/fon-2019-0368
Abstract: More oncology biologics are becoming available for subcutaneous (sc.) administration and are expected to provide useful therapeutic options. We evaluated evidence published in the past 5 years to assess the humanistic and economic impact of sc.… read more here.
Keywords: administration; humanistic economic; versus intravenous; economic impact ... See more keywords